550 related articles for article (PubMed ID: 28830541)
21. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
[TBL] [Abstract][Full Text] [Related]
22. The effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial.
You JS; Guo L; Huang M; Shi XL; Lin MD; Guo Z; Cao YL; Sun YZ; Xu Q; Qu WL; Liu HL; Chen JP
Trials; 2019 Dec; 20(1):719. PubMed ID: 31831051
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial.
Wang J; Shi J; Wei J; Wang J; Gao K; Li X; Chen J; Li S; Zhao H; Wang W
Trials; 2017 Oct; 18(1):468. PubMed ID: 29017565
[TBL] [Abstract][Full Text] [Related]
24. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.
Mecinaj A; Gulati G; Heck SL; Holte E; Fagerland MW; Larsen AI; Blix ES; Geisler J; Wethal T; Omland T
Cardiooncology; 2021 Sep; 7(1):33. PubMed ID: 34579775
[TBL] [Abstract][Full Text] [Related]
26. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
[TBL] [Abstract][Full Text] [Related]
27. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
28. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
29. The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients.
Wihandono A; Azhar Y; Abdurahman M; Hidayat S
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2847-2853. PubMed ID: 34582653
[TBL] [Abstract][Full Text] [Related]
30. Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial.
Heck SL; Gulati G; Hoffmann P; von Knobelsdorff-Brenkenhoff F; Storås TH; Ree AH; Gravdehaug B; Røsjø H; Steine K; Geisler J; Schulz-Menger J; Omland T
Eur Heart J Cardiovasc Imaging; 2018 May; 19(5):544-552. PubMed ID: 29106497
[TBL] [Abstract][Full Text] [Related]
31. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
Gulati G; Heck SL; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; von Knobelsdorff-Brenkenhoff F; Bratland Å; Storås TH; Hagve TA; Røsjø H; Steine K; Geisler J; Omland T
Eur Heart J; 2016 Jun; 37(21):1671-80. PubMed ID: 26903532
[TBL] [Abstract][Full Text] [Related]
32. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
[TBL] [Abstract][Full Text] [Related]
33. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
34. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.
Lenihan DJ; Stevens PL; Massey M; Plana JC; Araujo DM; Fanale MA; Fayad LE; Fisch MJ; Yeh ET
J Card Fail; 2016 Jun; 22(6):433-8. PubMed ID: 27079675
[TBL] [Abstract][Full Text] [Related]
35. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
36. Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.
Chung R; Maulik A; Hamarneh A; Hochhauser D; Hausenloy DJ; Walker JM; Yellon DM
Clin Cardiol; 2016 Feb; 39(2):72-82. PubMed ID: 26807534
[TBL] [Abstract][Full Text] [Related]
37. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
Nagy AC; Tolnay E; Nagykálnai T; Forster T
Neoplasma; 2006; 53(6):511-7. PubMed ID: 17167721
[TBL] [Abstract][Full Text] [Related]
38. The relationship between plasma hyaluronan levels and anthracycline-related cardiotoxicity in breast cancer patients.
Inanc MT; Karadavut S; Aytekin M; Duran AO; Derya M; Akpek M; Sahin O; Kalay N; Karaca H; Ozkan M; Inanc M
Int J Cardiol; 2016 Sep; 218():246-251. PubMed ID: 27236123
[TBL] [Abstract][Full Text] [Related]
39. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Di Persio S; Biondi-Zoccai GG
Int J Cardiol; 2009 Jun; 135(1):72-7. PubMed ID: 18572266
[TBL] [Abstract][Full Text] [Related]
40. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
